Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)

SCAN-B-rec: Infrastructure, Technology Platform and Clinical Research Development to Profile and Monitor Metastatic Breast Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03758976

Enrollment

2000

Registered

2018-11-29

Start date

2019-01-21

Completion date

2030-12-01

Last updated

2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Breast Cancer

Keywords

Metastatic breast cancer, Molecular profiling, Circulating tumor DNA, Circulating tumor cells

Brief summary

Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure. The main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response/resistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.

Interventions

DIAGNOSTIC_TESTBiopsies, blood

We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease. 2. Age \> 18 years. 3. Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2. 4. ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET). 5. Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion. 6. Signed informed consent according to ICH/GCP, and national/local regulations.

Exclusion criteria

Untreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.

Design outcomes

Primary

Measure	Time frame	Description
Survival	10 years	Prospective recording of treatment interventions and molecular characteristics in metastatic breast cancer patients until the date of Death.

Countries

Sweden

Contacts

Primary ContactKarolina Holm, PhD

karolina.holm@med.lu.se+46 730 84 17 61

Backup ContactChristel Reutersward, MSc

christel.reutersward@med.lu.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026